Work

“Silent Spring” revisited: Implications for breast cancer care

Year: 2025

Type: article

Abstract: sponsorship: AT: Johnson & Johnson, Bristol-Myer Squib, Pfizer, Gilead Sciences (stock ownership) ; Delphi Diagnostics, RTI international, Accord Bio-Pharma (consulting) ; Up-to-Date (royalties) . (Johnson Johnson, Bristol-Myer Squib, Pfizer, Gilead Sciences, RTI international, Accord Bio-Pharma, Up-to-Date)

Source: The Breast

DOI: 10.1016/j.breast.2025.104643

Authors: Seamus O'Reilly, Hans Wildiers, Alexandra Thomas

Institutions: Royal College of Surgeons in Ireland, Cancer Trials Ireland, Universitair Ziekenhuis Leuven, Duke University, Duke Cancer Institute

Language: English

Topic: Effects and risks of endocrine disrupting chemicals

Subfield: Health, Toxicology and Mutagenesis

Field: Environmental Science

Domain: Physical Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,200